GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rebus Hldgs Inc (OTCPK:RBSH) » Definitions » 3-Year EPS without NRI Growth Rate

Rebus Hldgs (Rebus Hldgs) 3-Year EPS without NRI Growth Rate : 96.40% (As of Jun. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Rebus Hldgs 3-Year EPS without NRI Growth Rate?

Rebus Hldgs's EPS without NRI for the three months ended in Jun. 2023 was $-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 96.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 95.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 83.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Rebus Hldgs was 97.90% per year. The lowest was -1678.50% per year. And the median was 21.60% per year.

Competitive Comparison of Rebus Hldgs's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Rebus Hldgs's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rebus Hldgs's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rebus Hldgs's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Rebus Hldgs's 3-Year EPS without NRI Growth Rate falls into.


Rebus Hldgs 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Rebus Hldgs  (OTCPK:RBSH) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Rebus Hldgs 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Rebus Hldgs's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Rebus Hldgs (Rebus Hldgs) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rebus Hldgs Inc (OTCPK:RBSH) » Definitions » 3-Year EPS without NRI Growth Rate
Comparable Companies
KRBP CNBX EVFM MYMX HGEN INFIQ RSPI PPCB CALA QBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
2629 Townsgate Road, Suite 215, Westlake Village, CA, USA, 91361
Website
http://www.rebus-corp.com
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.
Executives
John Robison Montgomery director 7647 BIRCHWOOD HILL RD, CROZET VA 22932
Richard E Buller director C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
Claire Thom director 31200 VIA COLINAS, #200, WESTLAKE VILLAGE CA 91362
Ronald L Shazer officer: Chief Medical Officer C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Christopher P. Lowe director, officer: President and CEO 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Scott Varde Ogilvie director 10880 WILSHIRE BLVD, SUITE 950, LOS ANGELES CA 90024
Bo Jesper Hansen director BIRKENWEG 16, MEGGEN V8 6045
Peter E Grebow director 41 MOORES ROAD, FRAZER PA 19355
Craig A Dionne director, 10 percent owner, officer: CEO,CFO, President 9901 IH 10 WEST, SUITE 800, SAN ANTONIO TX 78230
Russell Richerson 10 percent owner, officer: COO, Secretary 2511 N LOOP 1604 W, SUITE 204, SAN ANTONIO TX 78258
Kihong Kwon 10 percent owner 1015 E. CHAPMAN AVE, SUITE 201, FULLERTON CA 92831